Randomized placebo-controlled trial of interferon alpha-2b plus ribavirin with and without lactoferrin for chronic hepatitis C

Hepatology Research

Volumn 32, Issue 4, 2005, Pages 218-223

  Ishibashi, Yoko ^a   Takeda, Koichiro ^a   Tsukidate, Noriyuki ^a   Miyazaki, Hiroki ^a   Ohira, Koji ^a   Dosaka Akita, Hirotoshi ^a   Nishimura, Masaharu ^a   Suzuki, J ^b   Fujita, J ^b   Miura, A ^b   Sugai, N ^b   Furuya, K ^c   Sadaoka, K ^c   Suga, M ^c   Masutani, M ^d   Sato, S ^d   Takahashi, K ^e   Kitahama, S ^f   Dochin, A ^f  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kohnan Hospital   (Japan)

^c Hokkaido Social Insurance Hospital   (Japan)

^d Ebetsu City Hospital   (Japan)

^e Fukagawa Municipal General Hospital   (Japan)

^f SUNAGAWA CITY MEDICAL CENTER   (Japan)

Author keywords

Chronic hepatitis C; Interferon alpha 2b; Lactoferrin; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; HEMOGLOBIN; IRON; LACTOFERRIN; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STATISTICAL SIGNIFICANCE; TH1 CELL; TH2 CELL;

EID: 23944467709     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2005.03.018     Document Type: Article

References (41)

1. A.I. Sharara C.M. Hunt J.D. Hamilton Hepatitis C Ann Inter Med 125 1996 658-668
2. K. Tarao Y. Rino S. Takemiya et al. Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma Intervirology 43 2000 20-26
3. A. Kasahara N. Hayashi K. Mochizuki et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 27 1998 1394-1402
4. Y. Shiratori F. Imazeki M. Moriyama et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann Intern Med 132 2000 517-524
5. A.M. Di Bisceglie Hepatitis C and hepatocellular carcinoma Hepatology 26 Suppl. 1 1997 34S-38S
6. S. Takano O. Yokosuka F. Imazeki M. Tagawa M. Omata Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients Hepatology 21 1995 650-655
7. C. Niederau S. Lange T. Heintges et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study Hepatology 28 1998 1687-1695
8. J.G. McHutchison S.C. Gordon E.R. Schiff et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485-1492
9. G.L. Davis R. Esteban-Mur V. Rustgi et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N Engl J Med 339 1998 1493-1499
10. O. Reichard G. Norkrans A. Fryden J.H. Braconier A. Sonnerborg O. Weiland Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group Lancet 351 1998 83-87
11. S. Iino E. Tomita H. Kumada et al. Prediction of treatment outcome with daily high-dose IFN α-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: Relationship of baseline viral levels and viral dynamics during and after therapy Hepatol Res 30 2004 63-70
12. B. Lonnerdal S. Iyer Lactoferrin: Molecular structure and biological function Annu Rev Nutr 15 1995 93-110
13. P.F. Levay M. Viljoen Lactoferrin: A general review Haematologica 80 1995 252-267
14. K. Hasegawa W. Motsuchi S. Tanaka S. Dosako Inhibition with lactoferrin of in vitro infection with human herpes virus Jpn J Med Sci Biol 47 1994 73-85
15. T. Fujihara K. Hayashi Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea Arch Virol 140 1995 1469-1472
16. M.C. Defer B. Dugas O. Picard C. Damais Impairment of circulating lactoferrin in HIV-1 infection Cell Mol Biol 41 1995 417-421
17. M.C. Harmsen P.J. Swart M.P. de Bethune et al. Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro J Infect Dis 172 1995 380-388
18. M. Ikeda K. Sugiyama T. Tanaka et al. Lactoferrin markedly inhibit hepatitis C virus infection in cultured human hepatocytes Biochem Biophys Res Commun 245 1998 549-553
19. M. Yi S. Kaneko D.Y. Yu S. Murakami Hepatitis C virus envelope proteins bind lactoferrin J Virol 71 1997 5997-6002
20. M. Ikeda A. Nozaki K. Sugiyama et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells Virus Res 66 2000 51-63
21. M. Iwasa M. Kaito J. Ikoma et al. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b Am J Gasrtoenterol 97 2002 766-767
22. K. Tanaka M. Ikeda A. Nozaki et al. Lactoferrin inhibits hepatitis C virus viremia in patients with chronic hepatitis C: A pilot study Jpn J Cancer Res 90 1999 367-371
23. S. Okada K. Tanaka T. Sato et al. Dose-response trial of lactoferrin in patients with chronic hepatitis C Jpn J Cancer Res 93 2002 1063-1069
24. K. Ishii N. Takamura M. Shinohara et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months Hepatol Res 25 2003 226-233
25. N. Hirashima E. Orito K. Ohba et al. A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load Hepatol Res 29 2004 9-12
26. A.B. Miller B. Hoogstraten M. Staquet A. Winkler Reporting results of cancer treatment Cancer 47 1981 207-214
27. K. Kanai M. Kako H. Okamoto HCV genotypes in chronic hepatitis C and response to interferon Lancet 339 1992 1543
28. A. Tsubota K. Chayama K. Ikeda et al. Related articles, links abstract factors predictive of response to interferon-alpha therapy in hepatitis C virus infection Hepatology 19 1994 1088-1094
29. K. Hino S. Sainokami K. Shimoda et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C J Med Virol 42 1994 299-305
30. K. Yoshioka Y. Higashi M. Yamada et al. Predictive factors in the response to interferon therapy in chronic hepatitis C Liver 15 1995 57-62
31. T.L. Fong S.H. Han N.C. Tsai et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C J Hepatol 28 1998 369-374
32. J.K. Olynyk K.R. Reddy A.M. Di Bisceglie et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C Gastroenterology 108 1995 1104-1109
33. D.H. Van Thiel L. Friedlander S. Fagiuoli H.I. Wright W. Irish J.S. Gavaler Response to interferon a therapy is influenced by the iron content of the liver J Hepatol 20 1994 410-415
34. N. Arber M. Moshkowitz F. Konikoff et al. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection Dig Dis Sci 40 1995 2431-2433
35. C.M. Girelli C. Mirata E. Lesinigo A. Casiraghi Iron overload and response to alfa-interferon in chronic hepatitis C Am J Gastroenterol 90 1995 170-171
36. A.L. Barton B.F. Banner E.E. Cable H.L. Bonkovsky Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy Am J Clin Pathol 103 1995 419-424
37. R.J. Fontana J. Israel P. LeClair et al. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial Hepatology 31 2000 730-736
38. H.L. Bonkovsky B.F. Banner A.L. Rothman Iron and chronic viral hepatitis Hepatology 25 1997 759-768
39. H. Hayashi T. Takikawa N. Nishimura M. Yano T. Isomuar Sakomoto Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron Am J Gastroenterol 89 1994 986-988
40. R.B. Rubin A. Barton B.F. Banner H.L. Bonkovsky Iron and chronic viral hepatitis: Emerging evidence for an important interaction Dig Dis 13 1995 223-238
41. K. Ishii N. Takamura M. Shinohara et al. Intracellular cytokine analysis of CD4-positive T cells predictive of sustained response to interferon therapy for patients with chronic hepatitis C Dig Dis Sci 47 2002 778-783